Compare Stocks: CLPBY, BDX, EW, and IDXX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$191.95 +2.3%	$161.58	$127.59 ▼ $192.30	$52.90B	0.19	1.90 million shs	2.52 million shs
CLPBY Coloplast A/S	$6.88 +1.2%	$6.30	$5.64 ▼ $10.03	$15.51B	0.13	173,814 shs	80,210 shs
EW Edwards Lifesciences	$89.89 +0.1%	$89.21	$72.30 ▼ $96.29	$51.70B	0.85	4.00 million shs	2.82 million shs
IDXX IDEXX Laboratories	$556.93 +2.0%	$560.01	$518.55 ▼ $769.98	$43.88B	1.54	643,864 shs	485,742 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	0.00%	+4.80%	+25.32%	+29.91%	-3.66%
CLPBY Coloplast A/S	0.00%	+2.99%	+13.91%	+9.03%	-30.36%
EW Edwards Lifesciences	0.00%	-1.77%	+7.49%	+4.61%	+10.60%
IDXX IDEXX Laboratories	0.00%	+1.08%	+3.26%	-0.44%	-12.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$191.95 +2.3%	$161.58	$127.59 ▼ $192.30	$52.90B	0.19	1.90 million shs	2.52 million shs
CLPBY Coloplast A/S	$6.88 +1.2%	$6.30	$5.64 ▼ $10.03	$15.51B	0.13	173,814 shs	80,210 shs
EW Edwards Lifesciences	$89.89 +0.1%	$89.21	$72.30 ▼ $96.29	$51.70B	0.85	4.00 million shs	2.82 million shs
IDXX IDEXX Laboratories	$556.93 +2.0%	$560.01	$518.55 ▼ $769.98	$43.88B	1.54	643,864 shs	485,742 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	0.00%	+4.80%	+25.32%	+29.91%	-3.66%
CLPBY Coloplast A/S	0.00%	+2.99%	+13.91%	+9.03%	-30.36%
EW Edwards Lifesciences	0.00%	-1.77%	+7.49%	+4.61%	+10.60%
IDXX IDEXX Laboratories	0.00%	+1.08%	+3.26%	-0.44%	-12.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDX Becton, Dickinson and Company	2.41	Hold	$185.67	-3.27% Downside
CLPBY Coloplast A/S	2.33	Hold	N/A	N/A
EW Edwards Lifesciences	2.74	Moderate Buy	$100.27	11.55% Upside
IDXX IDEXX Laboratories	2.60	Moderate Buy	$747.00	34.13% Upside

Current Analyst Ratings Breakdown

Latest CLPBY, EW, BDX, and IDXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$180.00 ➝ $190.00
8/11/2026	IDXX IDEXX Laboratories	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$800.00 ➝ $710.00
8/7/2026	BDX Becton, Dickinson and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	BDX Becton, Dickinson and Company	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$195.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$175.00 ➝ $180.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Hold
8/7/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$198.00 ➝ $204.00
8/7/2026	BDX Becton, Dickinson and Company	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$161.00 ➝ $175.00
8/7/2026	BDX Becton, Dickinson and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$161.00 ➝ $170.00
8/6/2026	BDX Becton, Dickinson and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$210.00

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDX Becton, Dickinson and Company	$21.84B	2.42	$23.07 per share	8.32	$88.61 per share	2.17
CLPBY Coloplast A/S	$4.13B	3.75	$0.36 per share	19.19	$1.06 per share	6.49
EW Edwards Lifesciences	$6.07B	8.53	$2.85 per share	31.49	$18.63 per share	4.83
IDXX IDEXX Laboratories	$4.30B	10.19	$15.08 per share	36.92	$20.47 per share	27.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDX Becton, Dickinson and Company	$1.68B	$3.32	57.82	14.50	13.53	4.52%	14.79%	6.93%	11/5/2026 (Estimated)
CLPBY Coloplast A/S	$538.49M	$0.19	18.59	16.38	2.66	9.68%	38.81%	11.52%	11/3/2026 (Estimated)
EW Edwards Lifesciences	$1.07B	$1.74	51.66	26.52	2.26	15.43%	15.68%	12.05%	10/29/2026 (Estimated)
IDXX IDEXX Laboratories	$1.06B	$14.22	39.17	33.51	2.97	25.03%	71.96%	33.60%	11/2/2026 (Estimated)

Latest CLPBY, EW, BDX, and IDXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q3 2026	CLPBY Coloplast A/S	$0.10	$0.10	N/A	$0.10	$1.11 billion	$1.14 billion
8/6/2026	Q3 2026	BDX Becton, Dickinson and Company	$3.14	$3.23	+$0.09	$1.37	$4.89 billion	$4.98 billion
8/4/2026	Q2 2026	IDXX IDEXX Laboratories	$3.94	$4.27	+$0.33	$4.27	$1.20 billion	$1.22 billion
7/23/2026	Q2 2026	EW Edwards Lifesciences	$0.7430	$0.78	+$0.0370	$0.42	$1.70 billion	$1.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDX Becton, Dickinson and Company	$4.20	2.19%	+5.65%	126.51%	53 Years
CLPBY Coloplast A/S	$0.08	1.16%	N/A	42.11%	N/A
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A

Latest CLPBY, EW, BDX, and IDXX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	BDX Becton, Dickinson and Company	quarterly	$1.05	2.53%	9/9/2026	9/9/2026	9/30/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDX Becton, Dickinson and Company	0.55	0.87	0.51
CLPBY Coloplast A/S	1.66	1.75	1.09
EW Edwards Lifesciences	0.06	4.52	3.77
IDXX IDEXX Laboratories	0.19	1.17	0.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDX Becton, Dickinson and Company	86.97%
CLPBY Coloplast A/S	N/A
EW Edwards Lifesciences	79.46%
IDXX IDEXX Laboratories	87.84%

Insider Ownership

Company	Insider Ownership
BDX Becton, Dickinson and Company	0.40%
CLPBY Coloplast A/S	N/A
EW Edwards Lifesciences	0.31%
IDXX IDEXX Laboratories	0.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDX Becton, Dickinson and Company	72,000	275.54 million	274.44 million	Optionable
CLPBY Coloplast A/S	17,156	2.25 billion	N/A	Not Optionable
EW Edwards Lifesciences	16,000	575.80 million	574.02 million	Optionable
IDXX IDEXX Laboratories	11,000	78.78 million	78.16 million	Optionable

CLPBY, BDX, EW, and IDXX Headlines

Recent News About These Companies

Great Lakes Advisors LLC Takes $2.10 Million Position in IDEXX Laboratories, Inc. $IDXX

August 22 at 4:01 AM | marketbeat.com

Bank of New York Mellon Corp Purchases New Holdings in IDEXX Laboratories, Inc. $IDXX

August 22 at 3:19 AM | marketbeat.com

Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?

August 21 at 10:56 AM | zacks.com

IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve

August 20 at 12:41 PM | zacks.com

Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding

August 20 at 12:30 PM | insidermonkey.com

Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding

August 20 at 11:50 AM | finance.yahoo.com

Flossbach Von Storch SE Invests $9.09 Million in IDEXX Laboratories, Inc. $IDXX

August 20 at 4:16 AM | marketbeat.com

Danske Bank A S Buys New Stake in IDEXX Laboratories, Inc. $IDXX

August 20 at 4:08 AM | marketbeat.com

Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?

August 19, 2026 | zacks.com

IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors despite daily gains

August 19, 2026 | marketwatch.com

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

August 18, 2026 | seekingalpha.com

Plato Investment Management Ltd Takes $1.48 Million Position in IDEXX Laboratories, Inc. $IDXX

August 18, 2026 | marketbeat.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 16, 2026 | americanbankingnews.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts

August 16, 2026 | marketbeat.com

IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests

August 14, 2026 | marketbeat.com

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow

August 14, 2026 | seekingalpha.com

Handelsbanken Fonder AB Grows Position in IDEXX Laboratories, Inc. $IDXX

August 13, 2026 | marketbeat.com

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

August 12, 2026 | finance.yahoo.com

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

August 12, 2026 | zacks.com

NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX

August 10, 2026 | marketbeat.com

Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX

August 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLPBY, BDX, EW, and IDXX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

$191.95 +4.33 (+2.31%)

As of 08/21/2026 03:58 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Coloplast A/S OTCMKTS:CLPBY

$6.88 +0.08 (+1.18%)

As of 08/21/2026 03:59 PM Eastern

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Edwards Lifesciences NYSE:EW

$89.89 +0.06 (+0.07%)

As of 08/21/2026 03:58 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

IDEXX Laboratories NASDAQ:IDXX

$556.93 +11.07 (+2.03%)

As of 08/21/2026 04:00 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLPBY, EW, BDX, and IDXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLPBY, EW, BDX, and IDXX Earnings

Compare Dividends

Latest CLPBY, EW, BDX, and IDXX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLPBY, BDX, EW, and IDXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLPBY, BDX, EW, and IDXX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

Coloplast A/S OTCMKTS:CLPBY

Edwards Lifesciences NYSE:EW

IDEXX Laboratories NASDAQ:IDXX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools